Spyre Therapeutics, Inc. ($SYRE)
Filing Information
| Accession Number | 0001636282-26-000117 |
|---|---|
| Form Type | 4 |
| Filing Date | Oct 3, 2026 |
| Document | View SEC Filing |
Transactions
10
Total Shares
75,000
Total Value
$2,624,330.98
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Common Stock | โ | Sep 30, 2026 | Exercise/Conversion | 17,500 | $14.50 | $253,750.00 | 97,262 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Sep 30, 2026 | Sale | 17,500 | $89.89 | $1,573,075.00 | 79,762 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Oct 1, 2026 | Exercise/Conversion | 7,500 | $14.50 | $108,750.00 | 87,262 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Oct 1, 2026 | Sale | 600 | $89.07 | $53,442.00 | 86,662 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Oct 1, 2026 | Sale | 1,500 | $90.27 | $135,405.00 | 85,162 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Oct 1, 2026 | Sale | 2,100 | $91.92 | $193,032.00 | 83,062 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Oct 1, 2026 | Sale | 3,071 | $92.95 | $285,449.45 | 79,991 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Oct 1, 2026 | Sale | 229 | $93.57 | $21,427.53 | 79,762 | Direct | โ | View Details | |
Chief Financial Officer | Stock Option (Right to Buy) | Derivative | Sep 30, 2026 | Exercise/Conversion | 17,500 | $0.00 | $0.00 | 319,857 | Direct | โ | View Details | |
Chief Financial Officer | Stock Option (Right to Buy) | Derivative | Oct 1, 2026 | Exercise/Conversion | 7,500 | $0.00 | $0.00 | 312,357 | Direct | โ | View Details |